Your browser doesn't support javascript.
loading
Efficacy analysis of unrelated cord blood transplantation for 58 acute myelogenous leukemia patients / 中华血液学杂志
Chinese Journal of Hematology ; (12): 637-641, 2015.
Artigo em Chinês | WPRIM | ID: wpr-296184
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the therapeutic efficacy and related risk factors of acute myelogenous leukemia (AML) patients treated with unrelated cord blood transplantation (UCBT).</p><p><b>METHODS</b>A retrospective analysis was performed on the clinical data of 58 AML patients that consisted of 1 case of M0, 1 case M1, 35 cases M2, 3 cases M4, 14 cases M5, 3 cases M6, and 1 case acute mixed leukemia, respectively. Of them, 1 case AML secondary to myelodysplastic syndrome, and 36 in first complete remission (CR1), 14 in second complele remission (CR2), 8 in non- remission (NR), 43 cases were refractory or high-risk patients(70.1%). The median age was 14.5 years with the median weight of 45 kg, 49 patients received sUCBT and 9 dUCBT. All the patients conditioned with intensified myeloablative regimen and received a combination of Cyclosporine A(CsA)and mycophenolate mofetil(MMF)to prevent graft- versus- host disease(GVHD).</p><p><b>RESULTS</b>56 out of 58 patients achieved engraftment with implantation rate 96.6%. The median time of ANC≥0.5×10⁹/L was 17(12-37)days, and that of PLT≥20× 109/L 33(17-140)days respectively. 24 cases developed acute GVHD(aGVHD), the incidence rate of grade Ⅱ to Ⅳ aGVHD was 30.4%. The chronic GVHD(cGVHD)was occured in 7 patients of the 49 evaluable patients, all were limited. The estimated 3-year overall survival(OS)and disease-free survival (DFS)were(60.3±6.4)% and(60.1±6.5)% respectively. And the cumulative incidences of 3-year nonrelapse mortality(NRM)and relapse were 33.3% and 9.1% respectively. The 3- year OS rates of AML patients were(66.0 ± 6.7)% for CR and(25.0 ± 15.3)% for NR, differences were statistical significance.</p><p><b>CONCLUSION</b>For AML patients, UCBT was conducive to improve outcome with lower incidences of cGVHD and relapse, the patients after transplantation could obtain high quality of life.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Qualidade de Vida / Recidiva / Indução de Remissão / Leucemia Mieloide Aguda / Doença Aguda / Incidência / Estudos Retrospectivos / Ciclosporina / Transplante de Células-Tronco Hematopoéticas / Intervalo Livre de Doença Tipo de estudo: Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Adolescente / Humanos Idioma: Chinês Revista: Chinese Journal of Hematology Ano de publicação: 2015 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Qualidade de Vida / Recidiva / Indução de Remissão / Leucemia Mieloide Aguda / Doença Aguda / Incidência / Estudos Retrospectivos / Ciclosporina / Transplante de Células-Tronco Hematopoéticas / Intervalo Livre de Doença Tipo de estudo: Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Adolescente / Humanos Idioma: Chinês Revista: Chinese Journal of Hematology Ano de publicação: 2015 Tipo de documento: Artigo